Printer Friendly

DEPRENYL RESEARCH LTD. RECEIVES NOTIFICATION FROM LUNAR OF TAKEDA'S INTENT TO TERMINATE LICENSE AGREEMENT

 TORONTO, Dec. 31 /PRNewswire/ -- Deprenyl Research Limited ("Deprenyl") (NASDAQ:DEPLF) was informed today by Lunar Corp. ("Lunar") that Takeda Chemical Industries, Ltd. ("Takeda") has decided to terminate its license with Lunar's subsidiary Bone Care International, Inc. ("Bone Care") effective March 2, 1993. On that date, all of Takeda's rights to one-alpha D2, which rights relate to the countries of Japan, Taiwan, and South Korea, will revert back to Bone Care. Takeda will have no further responsibility for any of the development costs associated with this investigational new drug for osteoporosis. Takeda has indicated that its decision to terminate was based, among other things, on an analysis of preliminary spinal bone mineral density data obtained from a clinical study conducted at Creighton University which preliminary analysis showed no statistical difference between patients treated with one-alpha D2 and those patients on placebo.
 Bone Care has completed a detailed evaluation of the final data from the Creighton study. Bone Care's new evaluation corrected inaccuracies which existed in certain of the bone scans included in the preliminary analysis. These spinal bone scan corrections were confirmed by the same independent analysts. Bone Care's evaluation also excluded patients whose blood and urine analyses showed they did not take the drug or that they had strong evidence of a coexisting metabolic disorder in addition to osteoporosis. Bone Care's re-analysis of the corrected scans shows a statistically significant increase in spinal bone mineral density of over three percent in patients receiving one-alpha D2 as compared with patients on placebo. Bone Care's analysis did not show significant differences between treatment groups for whole body and femoral bone mineral density.
 Based on this analysis, Bone Care believes that the Creighton data support the conclusion that the drug is safe and efficacious in increasing spine density in osteoporosis but cautioned that this conclusion is tentative pending Creighton's own evaluation of these data.
 Bone Care has licensed Canadian rights to one-alpha D2 to Bone Health Inc., a subsidiary of Deprenyl. Bone Care and Lunar intend to aggressively pursue additional licensing partners for one-alpha D2.
 Deprenyl is completing its study of the re-analysis of the final data from the Creighton study and will be meeting over the weekend to determine its options.
 Deprenyl Research Limited is a Canadian Pharmaceutical Company with several development stage affiliates. It develops and markets pharmaceutical agents for neurologic diseases, chronic diseases and diseases of aging and dermatology.
 -0- 12/31/92
 /NOTE TO EDITORS: If you can make the 2 in one-alpha D2 a subscript, please do so. Otherwise, print it as shown/
 /CONTACT: Martin Barkin, M.D., president & CEO or Deborah Worobec, investor relations, 416-537-4372, both of Deprenyl Research Limited or Jim Tolan of O'Connor Biro & Associates, 708-498-2284, for Deprenyl Research Limited/
 (DEPLF)


CO: Deprenyl Research Limited; Lunar Corporation; Takeda Chemical
 Industries, Ltd. ST: Ontario IN: MTC SU: LIC


TM -- NY042 -- 1029 12/31/92 17:46 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 31, 1992
Words:481
Previous Article:WABASH NATIONAL CORPORATION ANNOUNCES SEC FILING FOR SALE OF COMMON STOCK BY THE COMPANY AND ITS NON-MANAGEMENT, PRINCIPAL HOLDERS
Next Article:AMEX EQUITY VOLUME UP 6.8 PERCENT OVER LAST YEAR; SETS ALL-TIME YEARLY HIGH OF 3.59 BILLION SHARES. OPTIONS VOLUME UP 5.9 PERCENT
Topics:


Related Articles
BONE HEALTH INC. & DEPRENYL RESEARCH LIMITED ANNOUNCE SMITHKLINE BEECHAM HAS TRANSFERRED BACK TO LUNAR CORP. ALL ITS RIGHTS TO ONE-ALPHA D-2
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
CANADIAN LICENSE FOR NEW NEUROLOGY DRUG ACQUIRED BY DEPRENYL RESEARCH LIMITED FROM LABORATOIRE L. LAFON OF FRANCE
LUNAR ANNOUNCES THAT ONE-ALPHA D2 WAS EFFECTIVE
DEPRENYL USA, INC. ENGAGES CANADIAN INVESTMENT DEALER
DEPRENYL USA INC. GRANTS MEDICIS RIGHT TO FIRST REFUSAL TO MARKET IN THE U.S.; POTENTIAL BREAKTHROUGH DRUG FOR SKIN CANCER, PSORIASIS, AND WARTS
DEPRENYL RESEARCH LIMITED AND NOVOPHARM LIMITED ANNOUNCE STRATEGIC ALLIANCE
SMITHKLINE BEECHAM AND TAKEDA SIGN LETTER OF INTENT FOR GENOMICS COLLABORATION
SMITHKLINE BEECHAM AND TAKEDA COMPLETE GENOMICS AGREEMENT; TWO COMPANIES TO COLLABORATE IN BOTH RESEARCH AND MARKETING
SYNSORB Biotech Inc. Forms Strategic Alliance With Japan's Largest Pharmaceutical Company

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters